Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that reports frequent updates related to its work in genetically defined rare diseases. Company news regularly highlights progress for its lead program, pociredir, an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD).
Investors and followers of FULC can expect news items covering clinical trial milestones, such as initial and updated data from the Phase 1b PIONEER trial of pociredir in adults with severe SCD. Fulcrum’s releases describe dose-escalation cohorts, changes in HbF levels, markers of hemolysis and anemia, and observations related to vaso-occlusive crises, along with safety and tolerability findings.
Fulcrum also issues corporate and financial announcements, including quarterly financial results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants. Additional news may feature participation in major medical and investor conferences, such as the American Society of Hematology Annual Meeting and the J.P. Morgan Healthcare Conference, where the company presents clinical and preclinical data.
Other updates include disclosures on early-stage programs, such as calmodulin pathway modulators for bone marrow failure syndromes and preclinical data for EED inhibitor candidates in oncology models, as well as routine items like inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). For readers tracking FULC, this news stream provides insight into the evolution of Fulcrum’s pipeline, its clinical development strategy in sickle cell disease, and its broader efforts in gene-expression modulation for rare diseases.
Fulcrum Therapeutics (Nasdaq: FULC) granted inducement non‑statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan in reliance on Nasdaq Listing Rule 5635(c)(4).
The company granted a total of 30,400 options at an exercise price of $10.84 per share, equal to the closing price on the grant effective date, January 5, 2026. Each option has a 10‑year term and vests over four years: 25% on the first anniversary of employment, then 6.25% quarterly for the following twelve quarters, subject to continued service.
Fulcrum Therapeutics (Nasdaq: FULC) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 10:30 a.m. ET / 7:30 a.m. PT.
A live webcast will be accessible via Fulcrum's Events and Presentations page and a replay will be available on the company's website for at least 30 days following the presentation.
Fulcrum Therapeutics (Nasdaq: FULC) priced an upsized underwritten public offering to raise approximately $175.0 million in gross proceeds. The offering consists of 11,851,853 shares of common stock at $13.50 per share and, in lieu of common stock to certain investors, 1,111,193 pre-funded warrants at $13.499 each (exercise price $0.001). Fulcrum granted underwriters a 30-day option to buy up to an additional 1,944,456 shares on the same terms. Net proceeds are intended primarily for general corporate purposes, including working capital, R&D and clinical trials, regulatory submissions, commercialization, and potential acquisitions.
The offering is expected to close on or about December 11, 2025 and is being made under an effective shelf registration previously declared effective by the SEC.
Fulcrum Therapeutics (Nasdaq: FULC) announced a proposed underwritten public offering of $150.0 million of common stock with a 30-day underwriter option to purchase up to an additional $22.5 million of shares. All shares are to be sold by the company under an effective shelf registration previously filed with the SEC. Book-running managers include J.P. Morgan, Leerink Partners, and Cantor, with Oppenheimer and Truist also participating.
Fulcrum intends to use net proceeds for general corporate purposes, including R&D, clinical trials, regulatory submissions, commercialization, capital expenditures, and potential acquisitions. The offering is subject to market and other conditions; final terms will appear in a prospectus supplement filed with the SEC.
Fulcrum Therapeutics (Nasdaq: FULC) reported positive initial results from the 20 mg cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease on Dec 6, 2025. At Week 6 (n=12) mean absolute fetal hemoglobin (HbF) rose from 7.1% to 16.9% (+9.9%), with 7 of 12 patients (58%) reaching ≥20% HbF. Among six patients reaching Week 12, mean fold induction exceeded 3.75x versus 2.4x in the 12 mg cohort. Markers of hemolysis and anemia improved (LDH -37%, indirect bilirubin -37%, reticulocytes -33%), mean hemoglobin +0.8 g/dL, and no treatment-related serious adverse events were reported.
Fulcrum Therapeutics (Nasdaq: FULC) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) for one newly hired employee on an effective date of December 1, 2025. The company granted 5,250 non-statutory stock options at an exercise price of $9.87 per share (the closing price on the grant date).
The options carry a 10-year term and vest over four years: 25% on the first anniversary of the employee’s start date, then 6.25% each quarter for the following 12 quarters, subject to continued service. The award was made pursuant to the company’s 2022 Inducement Stock Incentive Plan.
Fulcrum Therapeutics (Nasdaq: FULC) will host an investor event on December 7, 2025 at 7:00 a.m. ET to review new clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD).
The presentation will include initial clinical data from the 20 mg dose cohort and full data from the 12 mg dose cohort, followed by a live Q&A. The same data will be presented at the 67th ASH Annual Meeting. A replay will be available on the company website and registration is available via the Events and Presentations page.
Fulcrum Therapeutics (Nasdaq: FULC) announced inducement equity grants for new hires under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted an aggregate of 270,000 non-statutory stock options to two employees and a 50,000 performance-based option to a third employee, each with an exercise price of $9.02 per share (closing price on the grant effective date, Nov 3, 2025).
The 270,000 options carry a 10-year term and vest over four years (25% after one year, then 6.25% quarterly over 12 quarters). The 50,000 performance option vests after 12 months subject to continued eligibility and achievement of predefined performance objectives, and will be forfeited if objectives are not met within six months of the grant date.
Fulcrum Therapeutics (Nasdaq: FULC) will present new clinical and preclinical data at the 67th American Society of Hematology Annual Meeting on December 6–7, 2025.
Pociredir Phase 1b PIONEER results will include full data from the 12 mg cohort and initial data from the 20 mg cohort in adults with severe sickle cell disease and hydroxyurea intolerance/unresponsiveness. A poster (ID 1157) is scheduled for Dec 6 and was selected for a Poster Walk on Dec 7. Fulcrum will host a live and webcast investor event on Dec 7, 2025 at 7:00 a.m. ET.
Fulcrum Therapeutics (NASDAQ: FULC) reported Q3 2025 results and clinical updates on Oct 29, 2025. Key clinical news: encouraging Phase 1b PIONEER 12 mg cohort results showing dose-dependent fetal hemoglobin (HbF) increases, hemolysis marker improvements, total hemoglobin gains, VOC reduction trends, and no drug-related SAEs through 12 mg. Enrollment completed in the 20 mg cohort (n=12); data expected by year-end 2025. Financials: $200.6M cash and marketable securities as of Sept 30, 2025, with a cash runway into 2028. Q3 R&D $14.3M, G&A $7.6M, net loss $19.6M.
FAQ
What is the current stock price of Fulcrum Therapeutics (FULC)?
What is the market cap of Fulcrum Therapeutics (FULC)?
